Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trialJohannes F.E. Mann, Katherine R. Tuttle, Peter Rossing et al.|Nature Medicine|2024Cited by 152
Plasma GAD65, a Marker for Early β-Cell Loss After Intraportal Islet Cell Transplantation in Diabetic PatientsZhidong Ling, Daniël Pipeleers, Pieter Gillard et al.|The Journal of Clinical Endocrinology & Metabolism|2015Cited by 26